Explore the Potential with AI-Driven Innovation
This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.
We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.
The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.
We employ our advanced, specialised process to create targeted libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.
Key features that set our library apart include:
partner
Reaxense
upacc
Q6ZUT3
UPID:
FRMD7_HUMAN
Alternative names:
-
Alternative UPACC:
Q6ZUT3; C0LLJ3; Q5JX99
Background:
FERM domain-containing protein 7 plays a crucial role in neurite development and eye movement regulation, primarily through the activation of GTPase RAC1. Its involvement in gaze stability underscores its importance in neurological functions.
Therapeutic significance:
Linked to Nystagmus 1, congenital, X-linked, a condition characterized by involuntary eye movements, FERM domain-containing protein 7's study could lead to novel interventions for this and potentially other neurological disorders.